Literature DB >> 9309250

Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways.

M Croisy-Delcey1, A Croisy, S Mousset, M Letourneur, E Bisagni, A Jacquemin-Sablon, J Pierre.   

Abstract

Two genistein analogues (MD831 and MD833) have been synthesized and analyzed for their biological properties and their mechanism of action im comparison to genistein either in vitro or in intact cells. We showed that, in vitro, one of these compounds (MD831) inhibits the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR) as efficiently as genistein. However, treatment of A431 cells with these compounds did not result in any significant modification of EGFR tyrosine phosphorylation. Extracellular-signal regulated kinase (ERK) phosphorylation in cells stimulated by EGF was enhanced in the presence of MD831, whereas the other compounds, genistein and MD833, were able to activate the c-jun N-terminal kinase (JNK). This study showed that two structurally related compounds could elicit markedly different pharmacological effects on two signalling pathways, one involved in the mitogenic response and the other in the stress response. Such compounds may be useful to characterize signalling events involved in cell response to physiological stimuli.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309250     DOI: 10.1016/S0753-3322(97)83545-7

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Genistein-induced G2/M cell cycle arrest of human intestinal colon cancer Caco-2 cells is associated with Cyclin B1 and Chk2 down-regulation.

Authors:  Junkyu Han; Yui Kurita; Hiroko Isoda
Journal:  Cytotechnology       Date:  2013-06-21       Impact factor: 2.058

2.  Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Authors:  Bridgette M Collins-Burow; James W Antoon; Daniel E Frigo; Steven Elliott; Christopher B Weldon; Stephen M Boue; Barbara S Beckman; Tyler J Curiel; Jawed Alam; John A McLachlan; Matthew E Burow
Journal:  J Steroid Biochem Mol Biol       Date:  2012-05-24       Impact factor: 4.292

3.  Differences between human breast cell lines in susceptibility towards growth inhibition by genistein.

Authors:  K Dampier; E A Hudson; L M Howells; M M Manson; R A Walker; A Gescher
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

4.  A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.

Authors:  Masahiko Hirata; Yasukazu Kanai; Sadahiro Naka; Mitsuyoshi Yoshimoto; Shinya Kagawa; Keiji Matsumuro; Hideyuki Katsuma; Hiroshi Yamaguchi; Yasuhiro Magata; Yoshiro Ohmomo
Journal:  Ann Nucl Med       Date:  2013-03-15       Impact factor: 2.668

5.  Transgenic Soybean Production of Bioactive Human Epidermal Growth Factor (EGF).

Authors:  Yonghua He; Monica A Schmidt; Christopher Erwin; Jun Guo; Raphael Sun; Ken Pendarvis; Brad W Warner; Eliot M Herman
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

6.  Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.

Authors:  Valerie S Honndorf; Stefan Wiehr; Anna-Maria Rolle; Julia Schmitt; Luisa Kreft; Letitia Quintanilla-Martinez; Ursula Kohlhofer; Gerald Reischl; Andreas Maurer; Karsten Boldt; Michael Schwarz; Holger Schmidt; Bernd J Pichler
Journal:  Oncotarget       Date:  2016-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.